Listed in the December 27, 2023 extract; not in the current extract (September 22, 2026): PMS-Galantamine ER (02398370), PMS-Galantamine ER (02398389), PMS-Galantamine ER (02398397). Source: odb-formulary-ed43-extract-2023-12-27.xml; compared with odb-formulary-ed43-extract-2026-09-22.xml.
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Galantamine hydrobromide
15 Limited Use · 3 not a benefit
Auro-Galantamine ER · DIN 02425157 · 8 mg · extended release capsule
Limited Use, Reason for Use code 347, 348 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 347, 348 required
Write on scriptone applicable Reason for Use code, 347 or 348 (criteria below)
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Ontario Limited Use criteria, code 347, 348
Reason for Use code 347
Initial Trial: For patients with mild to moderate Alzheimer's Disease (Mini-Mental State Exam [MMSE] 10-26). Patients will be reimbursed for a period of up to 3 months after which continued treatment must be reassessed.
Network note: Maximum duration 3 months.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 348
Continuation: Further reimbursement will be made available to those patients whose disease has not progressed/deteriorated while on this drug. Patients must continue to have a MMSE score of 10-26.
Coverage limit:
LU Authorization Period: 1 year
1 brand, same coverage
Auro-Galantamine ER · DIN 02425157
Manufacturer: Auro Pharma Inc.; listing date 2014-09-25
Health Canada: Marketed since 2014-06-12 · brand AURO-GALANTAMINE ER · ATC N06DA04 GALANTAMINE · form Capsule (extended-release) · route Oral · ingredients GALANTAMINE (GALANTAMINE HYDROBROMIDE) 8 MG · company Auro pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordAuro-Galantamine ER: Formulary list price $1.25 per unit (the source does not state the unit; exact figure $1.2465). What the ministry pays, not the patient.
Ministry pays: $1.2465 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02425157)
Source record
DIN 02425157: Auro-Galantamine ER
Raw flags: sec12=Y, sec3=Y
Item: 120400031; group id 194; item number 0356; lccId 00027; manufacturer id AUR
Source form: ER Cap; strength: 8mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $1.2465; ministry $1.2465
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02425157
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90981
Interchangeable products
Galantamine ER · DIN 02443015 · $1.2465
Galantamine ER · DIN 02562154 · $1.2465
Mylan-Galantamine ER · DIN 02339439 · $1.2465
Pat-Galantamine ER · DIN 02316943 · $1.2465
Reminyl ER · DIN 02266717 · not recorded
Shortage status: resolved shortage (ended December 16, 2024); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02425157
Shortage record checked October 6, 2026
Galantamine ER · DIN 02443015 · 8 mg · extended release capsule
Limited Use, Reason for Use code 347, 348 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 347, 348 required
Write on scriptone applicable Reason for Use code, 347 or 348 (criteria below)
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Ontario Limited Use criteria, code 347, 348
Reason for Use code 347
Initial Trial: For patients with mild to moderate Alzheimer's Disease (Mini-Mental State Exam [MMSE] 10-26). Patients will be reimbursed for a period of up to 3 months after which continued treatment must be reassessed.
Network note: Maximum duration 3 months.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 348
Continuation: Further reimbursement will be made available to those patients whose disease has not progressed/deteriorated while on this drug. Patients must continue to have a MMSE score of 10-26.
Coverage limit:
LU Authorization Period: 1 year
1 brand, same coverage
Galantamine ER · DIN 02443015
Manufacturer: Sanis Health Inc.; listing date 2020-06-30
Health Canada: Marketed since 2016-01-11 · brand GALANTAMINE ER · ATC N06DA04 GALANTAMINE · form Capsule (extended-release) · route Oral · ingredients GALANTAMINE (GALANTAMINE HYDROBROMIDE) 8 MG · company Sanis health inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordGalantamine ER: Formulary list price $1.25 per unit (the source does not state the unit; exact figure $1.2465). What the ministry pays, not the patient.
Ministry pays: $1.2465 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02443015)
Source record
DIN 02443015: Galantamine ER
Raw flags: sec12=Y, sec3=Y
Item: 120400031; group id 194; item number 0356; lccId 00027; manufacturer id SAI
Source form: ER Cap; strength: 8mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $1.2465; ministry $1.2465
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02443015
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92757
Interchangeable products
Auro-Galantamine ER · DIN 02425157 · $1.2465
Galantamine ER · DIN 02562154 · $1.2465
Mylan-Galantamine ER · DIN 02339439 · $1.2465
Pat-Galantamine ER · DIN 02316943 · $1.2465
Reminyl ER · DIN 02266717 · not recorded
Shortage status: resolved shortage (ended June 13, 2025); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02443015
Shortage record checked October 6, 2026
Galantamine ER · DIN 02562154 · 8 mg · extended release capsule
Limited Use, Reason for Use code 347, 348 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 347, 348 required
Write on scriptone applicable Reason for Use code, 347 or 348 (criteria below)
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Ontario Limited Use criteria, code 347, 348
Reason for Use code 347
Initial Trial: For patients with mild to moderate Alzheimer's Disease (Mini-Mental State Exam [MMSE] 10-26). Patients will be reimbursed for a period of up to 3 months after which continued treatment must be reassessed.
Network note: Maximum duration 3 months.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 348
Continuation: Further reimbursement will be made available to those patients whose disease has not progressed/deteriorated while on this drug. Patients must continue to have a MMSE score of 10-26.
Coverage limit:
LU Authorization Period: 1 year
1 brand, same coverage
Galantamine ER · DIN 02562154
Manufacturer: Sivem Pharmaceuticals ULC; listing date 2026-08-31
Health Canada: Marketed since 2026-07-09 · brand GALANTAMINE ER · ATC N06DA04 GALANTAMINE · form Capsule (extended-release) · route Oral · ingredients GALANTAMINE (GALANTAMINE HYDROBROMIDE) 8 MG · company Sivem pharmaceuticals ulc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordGalantamine ER: Formulary list price $1.25 per unit (the source does not state the unit; exact figure $1.2465). What the ministry pays, not the patient.
Ministry pays: $1.2465 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02562154)
Source record
DIN 02562154: Galantamine ER
Raw flags: sec12=Y, sec3=Y
Item: 120400031; group id 194; item number 0356; lccId 00027; manufacturer id SIV
Source form: ER Cap; strength: 8mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $1.2465; ministry $1.2465
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02562154
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=106505
Interchangeable products
Auro-Galantamine ER · DIN 02425157 · $1.2465
Galantamine ER · DIN 02443015 · $1.2465
Mylan-Galantamine ER · DIN 02339439 · $1.2465
Pat-Galantamine ER · DIN 02316943 · $1.2465
Reminyl ER · DIN 02266717 · not recorded
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02562154
Shortage record checked October 6, 2026
Mylan-Galantamine ER · DIN 02339439 · 8 mg · extended release capsule
Limited Use, Reason for Use code 347, 348 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 347, 348 required
Write on scriptone applicable Reason for Use code, 347 or 348 (criteria below)
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Ontario Limited Use criteria, code 347, 348
Reason for Use code 347
Initial Trial: For patients with mild to moderate Alzheimer's Disease (Mini-Mental State Exam [MMSE] 10-26). Patients will be reimbursed for a period of up to 3 months after which continued treatment must be reassessed.
Network note: Maximum duration 3 months.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 348
Continuation: Further reimbursement will be made available to those patients whose disease has not progressed/deteriorated while on this drug. Patients must continue to have a MMSE score of 10-26.
Coverage limit:
LU Authorization Period: 1 year
1 brand, same coverage
Mylan-Galantamine ER · DIN 02339439
Manufacturer: Mylan Pharmaceuticals ULC; listing date 2011-03-15
Health Canada: Marketed since 2011-11-13 · brand MYLAN-GALANTAMINE ER · ATC N06DA04 GALANTAMINE · form Capsule (extended-release) · route Oral · ingredients GALANTAMINE (GALANTAMINE HYDROBROMIDE) 8 MG · company Mylan pharmaceuticals ulc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordMylan-Galantamine ER: Formulary list price $1.25 per unit (the source does not state the unit; exact figure $1.2465). What the ministry pays, not the patient.
Ministry pays: $1.2465 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02339439)
Source record
DIN 02339439: Mylan-Galantamine ER
Raw flags: sec12=Y, sec3=Y
Item: 120400031; group id 194; item number 0356; lccId 00027; manufacturer id MYL
Source form: ER Cap; strength: 8mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $1.2465; ministry $1.2465
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02339439
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=82505
Interchangeable products
Auro-Galantamine ER · DIN 02425157 · $1.2465
Galantamine ER · DIN 02443015 · $1.2465
Galantamine ER · DIN 02562154 · $1.2465
Pat-Galantamine ER · DIN 02316943 · $1.2465
Reminyl ER · DIN 02266717 · not recorded
Shortage status: resolved shortage (ended March 19, 2024); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02339439
Shortage record checked October 6, 2026
Pat-Galantamine ER · DIN 02316943 · 8 mg · extended release capsule
Limited Use, Reason for Use code 347, 348 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 347, 348 required
Write on scriptone applicable Reason for Use code, 347 or 348 (criteria below)
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Ontario Limited Use criteria, code 347, 348
Reason for Use code 347
Initial Trial: For patients with mild to moderate Alzheimer's Disease (Mini-Mental State Exam [MMSE] 10-26). Patients will be reimbursed for a period of up to 3 months after which continued treatment must be reassessed.
Network note: Maximum duration 3 months.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 348
Continuation: Further reimbursement will be made available to those patients whose disease has not progressed/deteriorated while on this drug. Patients must continue to have a MMSE score of 10-26.
Coverage limit:
LU Authorization Period: 1 year
1 brand, same coverage
Pat-Galantamine ER · DIN 02316943
Manufacturer: Patriot, A Division of Janssen Inc.; listing date 2011-05-19
Health Canada: Marketed since 2026-08-11 · brand GALANTAMINE ER · ATC N06DA04 GALANTAMINE · form Capsule (extended-release) · route Oral · ingredients GALANTAMINE (GALANTAMINE HYDROBROMIDE) 8 MG · company Essential pharma switzerland gmbh · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordPat-Galantamine ER: Formulary list price $1.25 per unit (the source does not state the unit; exact figure $1.2465). What the ministry pays, not the patient.
Ministry pays: $1.2465 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02316943)
Source record
DIN 02316943: Pat-Galantamine ER
Raw flags: sec12=Y, sec3=Y
Item: 120400031; group id 194; item number 0356; lccId 00027; manufacturer id PAR
Source form: ER Cap; strength: 8mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $1.2465; ministry $1.2465
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02316943
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80244
Interchangeable products
Auro-Galantamine ER · DIN 02425157 · $1.2465
Galantamine ER · DIN 02443015 · $1.2465
Galantamine ER · DIN 02562154 · $1.2465
Mylan-Galantamine ER · DIN 02339439 · $1.2465
Reminyl ER · DIN 02266717 · not recorded
Shortage status: resolved shortage (ended October 4, 2023); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02316943
Shortage record checked October 6, 2026
Auro-Galantamine ER · DIN 02425165 · 16 mg · extended release capsule
Limited Use, Reason for Use code 347, 348 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 347, 348 required
Write on scriptone applicable Reason for Use code, 347 or 348 (criteria below)
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Ontario Limited Use criteria, code 347, 348
Reason for Use code 347
Initial Trial: For patients with mild to moderate Alzheimer's Disease (Mini-Mental State Exam [MMSE] 10-26). Patients will be reimbursed for a period of up to 3 months after which continued treatment must be reassessed.
Network note: Maximum duration 3 months.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 348
Continuation: Further reimbursement will be made available to those patients whose disease has not progressed/deteriorated while on this drug. Patients must continue to have a MMSE score of 10-26.
Coverage limit:
LU Authorization Period: 1 year
1 brand, same coverage
Auro-Galantamine ER · DIN 02425165
Manufacturer: Auro Pharma Inc.; listing date 2014-09-25
Health Canada: Marketed since 2014-06-12 · brand AURO-GALANTAMINE ER · ATC N06DA04 GALANTAMINE · form Capsule (extended-release) · route Oral · ingredients GALANTAMINE (GALANTAMINE HYDROBROMIDE) 16 MG · company Auro pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordAuro-Galantamine ER: Formulary list price $1.25 per unit (the source does not state the unit; exact figure $1.2465). What the ministry pays, not the patient.
Ministry pays: $1.2465 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02425165)
Source record
DIN 02425165: Auro-Galantamine ER
Raw flags: sec12=Y, sec3=Y
Item: 120400029; group id 194; item number 0357; lccId 00027; manufacturer id AUR
Source form: ER Cap; strength: 16mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $1.2465; ministry $1.2465
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02425165
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90982
Interchangeable products
Galantamine ER · DIN 02443023 · $1.2465
Galantamine ER · DIN 02562162 · $1.2465
Mylan-Galantamine ER · DIN 02339447 · $1.2465
Pat-Galantamine ER · DIN 02316951 · $1.2465
Reminyl ER · DIN 02266725 · not recorded
Shortage status: resolved shortage (ended July 16, 2024); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02425165
Shortage record checked October 6, 2026
Galantamine ER · DIN 02443023 · 16 mg · extended release capsule
Limited Use, Reason for Use code 347, 348 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 347, 348 required
Write on scriptone applicable Reason for Use code, 347 or 348 (criteria below)
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Ontario Limited Use criteria, code 347, 348
Reason for Use code 347
Initial Trial: For patients with mild to moderate Alzheimer's Disease (Mini-Mental State Exam [MMSE] 10-26). Patients will be reimbursed for a period of up to 3 months after which continued treatment must be reassessed.
Network note: Maximum duration 3 months.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 348
Continuation: Further reimbursement will be made available to those patients whose disease has not progressed/deteriorated while on this drug. Patients must continue to have a MMSE score of 10-26.
Coverage limit:
LU Authorization Period: 1 year
1 brand, same coverage
Galantamine ER · DIN 02443023
Manufacturer: Sanis Health Inc.; listing date 2020-06-30
Health Canada: Marketed since 2016-01-11 · brand GALANTAMINE ER · ATC N06DA04 GALANTAMINE · form Capsule (extended-release) · route Oral · ingredients GALANTAMINE (GALANTAMINE HYDROBROMIDE) 16 MG · company Sanis health inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordGalantamine ER: Formulary list price $1.25 per unit (the source does not state the unit; exact figure $1.2465). What the ministry pays, not the patient.
Ministry pays: $1.2465 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02443023)
Source record
DIN 02443023: Galantamine ER
Raw flags: sec12=Y, sec3=Y
Item: 120400029; group id 194; item number 0357; lccId 00027; manufacturer id SAI
Source form: ER Cap; strength: 16mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $1.2465; ministry $1.2465
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02443023
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92758
Interchangeable products
Auro-Galantamine ER · DIN 02425165 · $1.2465
Galantamine ER · DIN 02562162 · $1.2465
Mylan-Galantamine ER · DIN 02339447 · $1.2465
Pat-Galantamine ER · DIN 02316951 · $1.2465
Reminyl ER · DIN 02266725 · not recorded
Shortage status: resolved shortage (ended April 3, 2024); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02443023
Shortage record checked October 6, 2026
Galantamine ER · DIN 02562162 · 16 mg · extended release capsule
Limited Use, Reason for Use code 347, 348 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 347, 348 required
Write on scriptone applicable Reason for Use code, 347 or 348 (criteria below)
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Ontario Limited Use criteria, code 347, 348
Reason for Use code 347
Initial Trial: For patients with mild to moderate Alzheimer's Disease (Mini-Mental State Exam [MMSE] 10-26). Patients will be reimbursed for a period of up to 3 months after which continued treatment must be reassessed.
Network note: Maximum duration 3 months.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 348
Continuation: Further reimbursement will be made available to those patients whose disease has not progressed/deteriorated while on this drug. Patients must continue to have a MMSE score of 10-26.
Coverage limit:
LU Authorization Period: 1 year
1 brand, same coverage
Galantamine ER · DIN 02562162
Manufacturer: Sivem Pharmaceuticals ULC; listing date 2026-08-31
Health Canada: Marketed since 2026-07-09 · brand GALANTAMINE ER · ATC N06DA04 GALANTAMINE · form Capsule (extended-release) · route Oral · ingredients GALANTAMINE (GALANTAMINE HYDROBROMIDE) 16 MG · company Sivem pharmaceuticals ulc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordGalantamine ER: Formulary list price $1.25 per unit (the source does not state the unit; exact figure $1.2465). What the ministry pays, not the patient.
Ministry pays: $1.2465 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02562162)
Source record
DIN 02562162: Galantamine ER
Raw flags: sec12=Y, sec3=Y
Item: 120400029; group id 194; item number 0357; lccId 00027; manufacturer id SIV
Source form: ER Cap; strength: 16mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $1.2465; ministry $1.2465
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02562162
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=106506
Interchangeable products
Auro-Galantamine ER · DIN 02425165 · $1.2465
Galantamine ER · DIN 02443023 · $1.2465
Mylan-Galantamine ER · DIN 02339447 · $1.2465
Pat-Galantamine ER · DIN 02316951 · $1.2465
Reminyl ER · DIN 02266725 · not recorded
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02562162
Shortage record checked October 6, 2026
Mylan-Galantamine ER · DIN 02339447 · 16 mg · extended release capsule
Limited Use, Reason for Use code 347, 348 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 347, 348 required
Write on scriptone applicable Reason for Use code, 347 or 348 (criteria below)
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Ontario Limited Use criteria, code 347, 348
Reason for Use code 347
Initial Trial: For patients with mild to moderate Alzheimer's Disease (Mini-Mental State Exam [MMSE] 10-26). Patients will be reimbursed for a period of up to 3 months after which continued treatment must be reassessed.
Network note: Maximum duration 3 months.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 348
Continuation: Further reimbursement will be made available to those patients whose disease has not progressed/deteriorated while on this drug. Patients must continue to have a MMSE score of 10-26.
Coverage limit:
LU Authorization Period: 1 year
1 brand, same coverage
Mylan-Galantamine ER · DIN 02339447
Manufacturer: Mylan Pharmaceuticals ULC; listing date 2011-03-15
Health Canada: Marketed since 2011-11-13 · brand MYLAN-GALANTAMINE ER · ATC N06DA04 GALANTAMINE · form Capsule (extended-release) · route Oral · ingredients GALANTAMINE (GALANTAMINE HYDROBROMIDE) 16 MG · company Mylan pharmaceuticals ulc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordMylan-Galantamine ER: Formulary list price $1.25 per unit (the source does not state the unit; exact figure $1.2465). What the ministry pays, not the patient.
Ministry pays: $1.2465 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02339447)
Source record
DIN 02339447: Mylan-Galantamine ER
Raw flags: sec12=Y, sec3=Y
Item: 120400029; group id 194; item number 0357; lccId 00027; manufacturer id MYL
Source form: ER Cap; strength: 16mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $1.2465; ministry $1.2465
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02339447
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=82506
Interchangeable products
Auro-Galantamine ER · DIN 02425165 · $1.2465
Galantamine ER · DIN 02443023 · $1.2465
Galantamine ER · DIN 02562162 · $1.2465
Pat-Galantamine ER · DIN 02316951 · $1.2465
Reminyl ER · DIN 02266725 · not recorded
Shortage status: resolved shortage (ended January 22, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02339447
Shortage record checked October 6, 2026
Pat-Galantamine ER · DIN 02316951 · 16 mg · extended release capsule
Limited Use, Reason for Use code 347, 348 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 347, 348 required
Write on scriptone applicable Reason for Use code, 347 or 348 (criteria below)
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Ontario Limited Use criteria, code 347, 348
Reason for Use code 347
Initial Trial: For patients with mild to moderate Alzheimer's Disease (Mini-Mental State Exam [MMSE] 10-26). Patients will be reimbursed for a period of up to 3 months after which continued treatment must be reassessed.
Network note: Maximum duration 3 months.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 348
Continuation: Further reimbursement will be made available to those patients whose disease has not progressed/deteriorated while on this drug. Patients must continue to have a MMSE score of 10-26.
Coverage limit:
LU Authorization Period: 1 year
1 brand, same coverage
Pat-Galantamine ER · DIN 02316951
Manufacturer: Patriot, A Division of Janssen Inc.; listing date 2011-05-19
Health Canada: Marketed since 2026-08-11 · brand GALANTAMINE ER · ATC N06DA04 GALANTAMINE · form Capsule (extended-release) · route Oral · ingredients GALANTAMINE (GALANTAMINE HYDROBROMIDE) 16 MG · company Essential pharma switzerland gmbh · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordPat-Galantamine ER: Formulary list price $1.25 per unit (the source does not state the unit; exact figure $1.2465). What the ministry pays, not the patient.
Ministry pays: $1.2465 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02316951)
Source record
DIN 02316951: Pat-Galantamine ER
Raw flags: sec12=Y, sec3=Y
Item: 120400029; group id 194; item number 0357; lccId 00027; manufacturer id PAR
Source form: ER Cap; strength: 16mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $1.2465; ministry $1.2465
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02316951
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80245
Interchangeable products
Auro-Galantamine ER · DIN 02425165 · $1.2465
Galantamine ER · DIN 02443023 · $1.2465
Galantamine ER · DIN 02562162 · $1.2465
Mylan-Galantamine ER · DIN 02339447 · $1.2465
Reminyl ER · DIN 02266725 · not recorded
Shortage status: resolved shortage (ended October 4, 2023); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02316951
Shortage record checked October 6, 2026
Auro-Galantamine ER · DIN 02425173 · 24 mg · extended release capsule
Limited Use, Reason for Use code 347, 348 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 347, 348 required
Write on scriptone applicable Reason for Use code, 347 or 348 (criteria below)
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Ontario Limited Use criteria, code 347, 348
Reason for Use code 347
Initial Trial: For patients with mild to moderate Alzheimer's Disease (Mini-Mental State Exam [MMSE] 10-26). Patients will be reimbursed for a period of up to 3 months after which continued treatment must be reassessed.
Network note: Maximum duration 3 months.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 348
Continuation: Further reimbursement will be made available to those patients whose disease has not progressed/deteriorated while on this drug. Patients must continue to have a MMSE score of 10-26.
Coverage limit:
LU Authorization Period: 1 year
1 brand, same coverage
Auro-Galantamine ER · DIN 02425173
Manufacturer: Auro Pharma Inc.; listing date 2014-09-25
Health Canada: Marketed since 2014-06-12 · brand AURO-GALANTAMINE ER · ATC N06DA04 GALANTAMINE · form Capsule (extended-release) · route Oral · ingredients GALANTAMINE (GALANTAMINE HYDROBROMIDE) 24 MG · company Auro pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordAuro-Galantamine ER: Formulary list price $1.25 per unit (the source does not state the unit; exact figure $1.2465). What the ministry pays, not the patient.
Ministry pays: $1.2465 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02425173)
Source record
DIN 02425173: Auro-Galantamine ER
Raw flags: sec12=Y, sec3=Y
Item: 120400030; group id 194; item number 0358; lccId 00027; manufacturer id AUR
Source form: ER Cap; strength: 24mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $1.2465; ministry $1.2465
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02425173
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90983
Interchangeable products
Galantamine ER · DIN 02443031 · $1.2465
Galantamine ER · DIN 02562170 · $1.2465
Mylan-Galantamine ER · DIN 02339455 · $1.2465
Pat-Galantamine ER · DIN 02316978 · $1.2465
Reminyl ER · DIN 02266733 · not recorded
Shortage status: resolved shortage (ended December 27, 2018); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02425173
Shortage record checked October 6, 2026
Galantamine ER · DIN 02443031 · 24 mg · extended release capsule
Limited Use, Reason for Use code 347, 348 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 347, 348 required
Write on scriptone applicable Reason for Use code, 347 or 348 (criteria below)
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Ontario Limited Use criteria, code 347, 348
Reason for Use code 347
Initial Trial: For patients with mild to moderate Alzheimer's Disease (Mini-Mental State Exam [MMSE] 10-26). Patients will be reimbursed for a period of up to 3 months after which continued treatment must be reassessed.
Network note: Maximum duration 3 months.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 348
Continuation: Further reimbursement will be made available to those patients whose disease has not progressed/deteriorated while on this drug. Patients must continue to have a MMSE score of 10-26.
Coverage limit:
LU Authorization Period: 1 year
1 brand, same coverage
Galantamine ER · DIN 02443031
Manufacturer: Sanis Health Inc.; listing date 2020-06-30
Health Canada: Marketed since 2016-01-11 · brand GALANTAMINE ER · ATC N06DA04 GALANTAMINE · form Capsule (extended-release) · route Oral · ingredients GALANTAMINE (GALANTAMINE HYDROBROMIDE) 24 MG · company Sanis health inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordGalantamine ER: Formulary list price $1.25 per unit (the source does not state the unit; exact figure $1.2465). What the ministry pays, not the patient.
Ministry pays: $1.2465 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02443031)
Source record
DIN 02443031: Galantamine ER
Raw flags: sec12=Y, sec3=Y
Item: 120400030; group id 194; item number 0358; lccId 00027; manufacturer id SAI
Source form: ER Cap; strength: 24mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $1.2465; ministry $1.2465
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02443031
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92759
Interchangeable products
Auro-Galantamine ER · DIN 02425173 · $1.2465
Galantamine ER · DIN 02562170 · $1.2465
Mylan-Galantamine ER · DIN 02339455 · $1.2465
Pat-Galantamine ER · DIN 02316978 · $1.2465
Reminyl ER · DIN 02266733 · not recorded
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02443031
Shortage record checked October 6, 2026
Galantamine ER · DIN 02562170 · 24 mg · extended release capsule
Limited Use, Reason for Use code 347, 348 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 347, 348 required
Write on scriptone applicable Reason for Use code, 347 or 348 (criteria below)
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Ontario Limited Use criteria, code 347, 348
Reason for Use code 347
Initial Trial: For patients with mild to moderate Alzheimer's Disease (Mini-Mental State Exam [MMSE] 10-26). Patients will be reimbursed for a period of up to 3 months after which continued treatment must be reassessed.
Network note: Maximum duration 3 months.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 348
Continuation: Further reimbursement will be made available to those patients whose disease has not progressed/deteriorated while on this drug. Patients must continue to have a MMSE score of 10-26.
Coverage limit:
LU Authorization Period: 1 year
1 brand, same coverage
Galantamine ER · DIN 02562170
Manufacturer: Sivem Pharmaceuticals ULC; listing date 2026-08-31
Health Canada: Marketed since 2026-07-09 · brand GALANTAMINE ER · ATC N06DA04 GALANTAMINE · form Capsule (extended-release) · route Oral · ingredients GALANTAMINE (GALANTAMINE HYDROBROMIDE) 24 MG · company Sivem pharmaceuticals ulc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordGalantamine ER: Formulary list price $1.25 per unit (the source does not state the unit; exact figure $1.2465). What the ministry pays, not the patient.
Ministry pays: $1.2465 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02562170)
Source record
DIN 02562170: Galantamine ER
Raw flags: sec12=Y, sec3=Y
Item: 120400030; group id 194; item number 0358; lccId 00027; manufacturer id SIV
Source form: ER Cap; strength: 24mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $1.2465; ministry $1.2465
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02562170
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=106507
Interchangeable products
Auro-Galantamine ER · DIN 02425173 · $1.2465
Galantamine ER · DIN 02443031 · $1.2465
Mylan-Galantamine ER · DIN 02339455 · $1.2465
Pat-Galantamine ER · DIN 02316978 · $1.2465
Reminyl ER · DIN 02266733 · not recorded
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02562170
Shortage record checked October 6, 2026
Mylan-Galantamine ER · DIN 02339455 · 24 mg · extended release capsule
Limited Use, Reason for Use code 347, 348 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 347, 348 required
Write on scriptone applicable Reason for Use code, 347 or 348 (criteria below)
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Ontario Limited Use criteria, code 347, 348
Reason for Use code 347
Initial Trial: For patients with mild to moderate Alzheimer's Disease (Mini-Mental State Exam [MMSE] 10-26). Patients will be reimbursed for a period of up to 3 months after which continued treatment must be reassessed.
Network note: Maximum duration 3 months.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 348
Continuation: Further reimbursement will be made available to those patients whose disease has not progressed/deteriorated while on this drug. Patients must continue to have a MMSE score of 10-26.
Coverage limit:
LU Authorization Period: 1 year
1 brand, same coverage
Mylan-Galantamine ER · DIN 02339455
Manufacturer: Mylan Pharmaceuticals ULC; listing date 2011-03-15
Health Canada: Marketed since 2011-11-13 · brand MYLAN-GALANTAMINE ER · ATC N06DA04 GALANTAMINE · form Capsule (extended-release) · route Oral · ingredients GALANTAMINE (GALANTAMINE HYDROBROMIDE) 24 MG · company Mylan pharmaceuticals ulc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordMylan-Galantamine ER: Formulary list price $1.25 per unit (the source does not state the unit; exact figure $1.2465). What the ministry pays, not the patient.
Ministry pays: $1.2465 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02339455)
Source record
DIN 02339455: Mylan-Galantamine ER
Raw flags: sec12=Y, sec3=Y
Item: 120400030; group id 194; item number 0358; lccId 00027; manufacturer id MYL
Source form: ER Cap; strength: 24mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $1.2465; ministry $1.2465
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02339455
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=82507
Interchangeable products
Auro-Galantamine ER · DIN 02425173 · $1.2465
Galantamine ER · DIN 02443031 · $1.2465
Galantamine ER · DIN 02562170 · $1.2465
Pat-Galantamine ER · DIN 02316978 · $1.2465
Reminyl ER · DIN 02266733 · not recorded
Shortage status: resolved shortage (ended May 20, 2025); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02339455
Shortage record checked October 6, 2026
Pat-Galantamine ER · DIN 02316978 · 24 mg · extended release capsule
Limited Use, Reason for Use code 347, 348 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 347, 348 required
Write on scriptone applicable Reason for Use code, 347 or 348 (criteria below)
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Ontario Limited Use criteria, code 347, 348
Reason for Use code 347
Initial Trial: For patients with mild to moderate Alzheimer's Disease (Mini-Mental State Exam [MMSE] 10-26). Patients will be reimbursed for a period of up to 3 months after which continued treatment must be reassessed.
Network note: Maximum duration 3 months.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 348
Continuation: Further reimbursement will be made available to those patients whose disease has not progressed/deteriorated while on this drug. Patients must continue to have a MMSE score of 10-26.
Coverage limit:
LU Authorization Period: 1 year
1 brand, same coverage
Pat-Galantamine ER · DIN 02316978
Manufacturer: Patriot, A Division of Janssen Inc.; listing date 2011-05-19
Health Canada: Marketed since 2026-08-11 · brand GALANTAMINE ER · ATC N06DA04 GALANTAMINE · form Capsule (extended-release) · route Oral · ingredients GALANTAMINE (GALANTAMINE HYDROBROMIDE) 24 MG · company Essential pharma switzerland gmbh · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordPat-Galantamine ER: Formulary list price $1.25 per unit (the source does not state the unit; exact figure $1.2465). What the ministry pays, not the patient.
Ministry pays: $1.2465 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02316978)
Source record
DIN 02316978: Pat-Galantamine ER
Raw flags: sec12=Y, sec3=Y
Item: 120400030; group id 194; item number 0358; lccId 00027; manufacturer id PAR
Source form: ER Cap; strength: 24mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $1.2465; ministry $1.2465
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02316978
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80246
Interchangeable products
Auro-Galantamine ER · DIN 02425173 · $1.2465
Galantamine ER · DIN 02443031 · $1.2465
Galantamine ER · DIN 02562170 · $1.2465
Mylan-Galantamine ER · DIN 02339455 · $1.2465
Reminyl ER · DIN 02266733 · not recorded
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02316978
Shortage record checked October 6, 2026
Reminyl ER · DIN 02266717 · 8 mg · extended release capsule
Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2017-04-03 — choose a marketed DIN from the same-category list.Discontinued April 3, 2017 · checked October 5, 2026
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2017-04-03 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives; Health Canada lists this DIN as Cancelled post market since 2017-04-03 — choose a marketed DIN from the same-category list.
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Ontario Limited Use criteria, code 347, 348
Reason for Use code 347
Initial Trial: For patients with mild to moderate Alzheimer's Disease (Mini-Mental State Exam [MMSE] 10-26). Patients will be reimbursed for a period of up to 3 months after which continued treatment must be reassessed.
Network note: Maximum duration 3 months.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 348
Continuation: Further reimbursement will be made available to those patients whose disease has not progressed/deteriorated while on this drug. Patients must continue to have a MMSE score of 10-26.
Coverage limit:
LU Authorization Period: 1 year
1 brand, same coverage
Reminyl ER · DIN 02266717
Manufacturer: Janssen Inc.; listing date 2006-01-12
Health Canada: Cancelled post market since 2017-04-03 · brand REMINYL ER · ATC N06DA04 GALANTAMINE · form Capsule (extended-release) · route Oral · ingredients GALANTAMINE (GALANTAMINE HYDROBROMIDE) 8 MG · company Janssen inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordReminyl ER: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02266717)
Source record
DIN 02266717: Reminyl ER
Raw flags: notABenefit=Y, sec3=Y
Item: 120400031; group id 194; item number 0356; lccId 00027; manufacturer id JAN
Source form: ER Cap; strength: 8mg
Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02266717
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=75213
Interchangeable products
Auro-Galantamine ER · DIN 02425157 · $1.2465
Galantamine ER · DIN 02443015 · $1.2465
Galantamine ER · DIN 02562154 · $1.2465
Mylan-Galantamine ER · DIN 02339439 · $1.2465
Pat-Galantamine ER · DIN 02316943 · $1.2465
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02266717
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since April 3, 2017 — choose a marketed DIN from the same-category list.
Reminyl ER · DIN 02266725 · 16 mg · extended release capsule
Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2017-03-31 — choose a marketed DIN from the same-category list.Discontinued March 31, 2017 · checked October 5, 2026
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2017-03-31 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives; Health Canada lists this DIN as Cancelled post market since 2017-03-31 — choose a marketed DIN from the same-category list.
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Ontario Limited Use criteria, code 347, 348
Reason for Use code 347
Initial Trial: For patients with mild to moderate Alzheimer's Disease (Mini-Mental State Exam [MMSE] 10-26). Patients will be reimbursed for a period of up to 3 months after which continued treatment must be reassessed.
Network note: Maximum duration 3 months.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 348
Continuation: Further reimbursement will be made available to those patients whose disease has not progressed/deteriorated while on this drug. Patients must continue to have a MMSE score of 10-26.
Coverage limit:
LU Authorization Period: 1 year
1 brand, same coverage
Reminyl ER · DIN 02266725
Manufacturer: Janssen Inc.; listing date 2006-01-12
Health Canada: Cancelled post market since 2017-03-31 · brand REMINYL ER · ATC N06DA04 GALANTAMINE · form Capsule (extended-release) · route Oral · ingredients GALANTAMINE (GALANTAMINE HYDROBROMIDE) 16 MG · company Janssen inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordReminyl ER: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02266725)
Source record
DIN 02266725: Reminyl ER
Raw flags: notABenefit=Y, sec3=Y
Item: 120400029; group id 194; item number 0357; lccId 00027; manufacturer id JAN
Source form: ER Cap; strength: 16mg
Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02266725
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=75214
Interchangeable products
Auro-Galantamine ER · DIN 02425165 · $1.2465
Galantamine ER · DIN 02443023 · $1.2465
Galantamine ER · DIN 02562162 · $1.2465
Mylan-Galantamine ER · DIN 02339447 · $1.2465
Pat-Galantamine ER · DIN 02316951 · $1.2465
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02266725
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since March 31, 2017 — choose a marketed DIN from the same-category list.
Reminyl ER · DIN 02266733 · 24 mg · extended release capsule
Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2017-04-04 — choose a marketed DIN from the same-category list.Discontinued April 4, 2017 · checked October 5, 2026
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2017-04-04 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives; Health Canada lists this DIN as Cancelled post market since 2017-04-04 — choose a marketed DIN from the same-category list.
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Ontario Limited Use criteria, code 347, 348
Reason for Use code 347
Initial Trial: For patients with mild to moderate Alzheimer's Disease (Mini-Mental State Exam [MMSE] 10-26). Patients will be reimbursed for a period of up to 3 months after which continued treatment must be reassessed.
Network note: Maximum duration 3 months.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 348
Continuation: Further reimbursement will be made available to those patients whose disease has not progressed/deteriorated while on this drug. Patients must continue to have a MMSE score of 10-26.
Coverage limit:
LU Authorization Period: 1 year
1 brand, same coverage
Reminyl ER · DIN 02266733
Manufacturer: Janssen Inc.; listing date 2006-01-12
Health Canada: Cancelled post market since 2017-04-04 · brand REMINYL ER · ATC N06DA04 GALANTAMINE · form Capsule (extended-release) · route Oral · ingredients GALANTAMINE (GALANTAMINE HYDROBROMIDE) 24 MG · company Janssen inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordReminyl ER: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02266733)
Source record
DIN 02266733: Reminyl ER
Raw flags: notABenefit=Y, sec3=Y
Item: 120400030; group id 194; item number 0358; lccId 00027; manufacturer id JAN
Source form: ER Cap; strength: 24mg
Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02266733
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=75215
Interchangeable products
Auro-Galantamine ER · DIN 02425173 · $1.2465
Galantamine ER · DIN 02443031 · $1.2465
Galantamine ER · DIN 02562170 · $1.2465
Mylan-Galantamine ER · DIN 02339455 · $1.2465
Pat-Galantamine ER · DIN 02316978 · $1.2465
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02266733
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since April 4, 2017 — choose a marketed DIN from the same-category list.
Other products in the same Health Canada class (N06DA): coverage varies; not interchangeable
- Donepezil (Aricept RDT): limited Use 347, 348, not a benefit
- Rivastigmine (Exelon): limited Use 347, 348, not a benefit